BriaCell Therapeutics Corp. (BCTX)
After hours:
- Baystreet
Stocks in play: BriaCell Therapeutics Corp
Announces that its lead product candidate, Bria-IMT™, will be featured in three posters during the 2022 ...
- GlobeNewswire
BriaCell to Present New Clinical Data at the 2022 San Antonio Breast Cancer Symposium® December 6th and 7th
PHILADELPHIA and VANCOUVER, British Columbia, Sept. 28, 2022 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnology company specializing in targeted immunotherapies for cancer, is pleased to announce that its lead product candidate, Bria-IMT™, will be featured in three posters during the 2022 San Antonio Breast Cancer Symposium® taking place December 6-10, 2022 at the Henry B. Gonzalez Convention Center in Sa
- GlobeNewswire
BriaCell Partners with Caris Life Sciences® to Expand Patient Outreach and Molecular Profiling
PHILADELPHIA and VANCOUVER, British Columbia, Sept. 14, 2022 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnology company specializing in targeted immunotherapies for cancer, announces that it has signed an agreement with Caris Life Sciences® (Caris), a leading molecular science and technology company actively developing and delivering innovative solutions to revolutionize healthcare. “Our goal is to develo
